Coagulopathy Associated with COVID-19

An international panel provides guidance on prognostic variables and management strategies for COVID-19–associated coagulopathy.

Lymphopenia is a common hematological abnormality among patients with COVID-19. In addition to respiratory failure, patients with severe illness are also likely to have coagulopathy. Practical guidance that can be applied in higher- and lower-resource healthcare settings is needed. As such, on behalf of the International Society on Thrombosis and Haemostasis, experts have created an interim guidance statement on the management of coagulopathy in COVID-19 patients.

Key points include the following:

Upon presentation of COVID-19, the measurements advised, in order of importance, are of d-dimer, prothrombin time, and platelet counts.
Increased d-dimers are commonly reported in patients with severe illness and may predict mortality.
Prolongation in…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Coagulopathy Associated with COVID-19

Topics

Reviewing Author